Mesothelioma Prognosis - Revision history

MesotheliomaSupport: Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

2026-05-14T23:25:42Z

Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

← Older revision		Revision as of 23:25, 14 May 2026
Line 396:		Line 396:

	'''Legal Resources:'''		'''Legal Resources:'''
	* [https://dandell.com/ Danziger & De Llano] — Experienced mesothelioma attorneys offering free case evaluations. Call '''(~~866~~) ~~222~~-~~9990~~''' for a confidential consultation.<ref name="dandell-home" />		* [https://dandell.com/ Danziger & De Llano] — Experienced mesothelioma attorneys offering free case evaluations. Call '''(855) 699-5441''' for a confidential consultation.<ref name="dandell-home" />
	* [https://mesotheliomalawyersnearme.com/ Mesothelioma Lawyers Near Me] — Find qualified mesothelioma attorneys in your area and access the free case evaluation quiz.		* [https://mesotheliomalawyersnearme.com/ Mesothelioma Lawyers Near Me] — Find qualified mesothelioma attorneys in your area and access the free case evaluation quiz.
	* [https://www.mesotheliomalawyercenter.org/ Mesothelioma Lawyer Center] — Legal resources and attorney matching services for mesothelioma families.<ref name="mlc-home" />		* [https://www.mesotheliomalawyercenter.org/ Mesothelioma Lawyer Center] — Legal resources and attorney matching services for mesothelioma families.<ref name="mlc-home" />

MesotheliomaSupport: Fix 7b: demote body H1 to H2 (ALFRED audit #6922)

2026-05-14T23:07:18Z

Fix 7b: demote body H1 to H2 (ALFRED audit #6922)

← Older revision		Revision as of 23:07, 14 May 2026
Line 34:		Line 34:
	\|}		\|}

	= Mesothelioma Prognosis =		== Mesothelioma Prognosis ==

	== Overview ==		== Overview ==

MesotheliomaSupport: Add ECOG Performance Status section with verified PMIDs (CheckMate 743 Baas 2021 Lancet, Scherpereel 2026 JCO 5-year, Wang 2021 peritoneal MPeM ECOG, Panou 2025 Danish PM guidelines); CLEO PASS event 4998; bus event 4971

2026-05-03T13:18:02Z

Add ECOG Performance Status section with verified PMIDs (CheckMate 743 Baas 2021 Lancet, Scherpereel 2026 JCO 5-year, Wang 2021 peritoneal MPeM ECOG, Panou 2025 Danish PM guidelines); CLEO PASS event 4998; bus event 4971

← Older revision		Revision as of 13:18, 3 May 2026
Line 6:		Line 6:
	\|author=Danziger & De Llano Legal Team		\|author=Danziger & De Llano Legal Team
	\|published_time=2026-03-08		\|published_time=2026-03-08
	~~\|type=Article~~		}}
	~~\|twitter_card=summary_large_image~~}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
Line 40:		Line 39:

	Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />		Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />

	~~== At-a-Glance ==~~

	'''Mesothelioma prognosis at a glance:'''		'''Mesothelioma prognosis at a glance:'''
Line 50:		Line 47:
	* '''Age under 50 means 39% five-year survival''' — compared to just 4.5% for patients 75 and older, a nearly 9-fold difference		* '''Age under 50 means 39% five-year survival''' — compared to just 4.5% for patients 75 and older, a nearly 9-fold difference
	* '''PLECH score (2025) predicts survival most accurately''' — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems		* '''PLECH score (2025) predicts survival most accurately''' — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems
	* '''NLR ≥5 signals ~~2.7 times~~ higher mortality''' — one-year survival drops ~~from 60% to 26% based on~~ this simple blood test ratio		* '''Elevated NLR signals significantly higher mortality''' — one-year survival drops substantially when this simple blood test ratio is high
	* '''Peritoneal patients with complete surgery survive 8.7 years''' — median 104 months after cytoreductive surgery with HIPEC		* '''Peritoneal patients with complete surgery survive 8.7 years''' — median 104 months after cytoreductive surgery with HIPEC
	* '''High-volume centers reduce surgical death by 31%''' — 10.0% versus 14.6% ninety-day mortality at specialized facilities		* '''High-volume centers reduce surgical death by 31%''' — 10.0% versus 14.6% ninety-day mortality at specialized facilities



	== Key Facts ==		== Key Facts ==
Line 69:		Line 64:
	* '''Age Effect:''' Under 50: 39.2% five-year survival; 75+: 4.5% five-year survival — nearly 9-fold difference<ref name="factors-survival" />		* '''Age Effect:''' Under 50: 39.2% five-year survival; 75+: 4.5% five-year survival — nearly 9-fold difference<ref name="factors-survival" />
	* '''PLECH Score (2025):''' AUC 0.70 for 1-year overall survival prediction, outperforming CALGB (0.60) and EORTC (0.57)<ref name="plech" />		* '''PLECH Score (2025):''' AUC 0.70 for 1-year overall survival prediction, outperforming CALGB (0.60) and EORTC (0.57)<ref name="plech" />
	* '''NLR Biomarker:''' ~~Neutrophil~~-to-lymphocyte ratio ~~≥5 carries HR 2.7 — 1-year~~ survival ~~drops from 60% to 26%~~<ref name="nlr-meta" />		* '''NLR Biomarker:''' Elevated neutrophil-to-lymphocyte ratio is associated with significantly reduced survival<ref name="nlr-meta" />
	* '''Peritoneal with CC-0:''' Complete cytoreduction achieves median 104 months (8.7 years) survival<ref name="mnet-hipec" />		* '''Peritoneal with CC-0:''' Complete cytoreduction achieves median 104 months (8.7 years) survival<ref name="mnet-hipec" />
	* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />		* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />
Line 192:		Line 187:
	\| style="padding:5px 25px 20px; text-align:right;" \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano		\| style="padding:5px 25px 20px; text-align:right;" \| '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
	\|}		\|}

			== How Does ECOG Performance Status Predict Outcomes? ==

			The Eastern Cooperative Oncology Group (ECOG) Performance Status scale — a 0-to-5 clinician-rated measure of functional capacity — is among the strongest independent prognostic factors in mesothelioma and the gating eligibility criterion for nearly every disease-modifying treatment. ECOG 0 (fully active) and ECOG 1 (restricted in strenuous activity but ambulatory) define the population eligible for aggressive multimodal therapy, immunotherapy, and clinical trials. ECOG 2 patients face a clinical "gray zone" where toxicity risk rises sharply but selected therapies remain available. ECOG ≥3 generally contraindicates systemic therapy in favor of palliative care.<ref name="ecog-mpem-2021" />

			A retrospective analysis of malignant peritoneal mesothelioma patients treated with cytoreductive surgery confirmed ECOG score as an independent prognostic factor in multivariate Cox regression (odds ratio 3.91, 95% CI 1.035–3.572; p=0.017), with ECOG <3 patients achieving 77.27% survival versus 40.91% for ECOG ≥3 patients on univariate analysis (p=0.014).<ref name="ecog-mpem-2021" /> The pattern aligns with broader oncology evidence demonstrating that immunotherapy and aggressive systemic therapy benefit drops sharply for patients with ECOG PS ≥2 across solid tumor types.

			The pivotal CheckMate 743 trial, which established nivolumab plus ipilimumab as the first new FDA-approved first-line regimen for unresectable pleural mesothelioma in over 15 years, restricted enrollment to patients with ECOG PS 0 or 1: 38% of the immunotherapy arm had PS 0 and 62% had PS 1.<ref name="checkmate743-bla" /> The trial reported median overall survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy in the overall population, with the histology-stratified analysis showing the largest absolute benefit in non-epithelioid disease (16.9 months vs. 8.8 months).<ref name="checkmate743-bla" /> Five-year follow-up data published in 2026 confirmed durable survival benefit, with 14% of patients alive at five years on the immunotherapy combination versus 6% on chemotherapy.<ref name="checkmate743-5yr" />

			Performance status is also embedded in every validated mesothelioma prognostic scoring system. The PLECH score assigns a +1 point penalty for ECOG ≥2; the EORTC and CALGB scores both include performance status as a core variable; and Danish clinical guidelines published in 2025 explicitly limit surgical eligibility to patients with ECOG PS 0–1, age below 75, preserved cardiac and pulmonary function, Stage I–IIIA disease, and epithelioid or low-sarcomatoid biphasic histology.<ref name="danish-pm-2025" /><ref name="plech" />

	== What Role Do Blood Markers Play in Prognosis? ==		== What Role Do Blood Markers Play in Prognosis? ==
Line 205:		Line 210:
	\|-		\|-
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| '''Neutrophil-to-Lymphocyte Ratio (NLR)'''		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| '''Neutrophil-to-Lymphocyte Ratio (NLR)'''
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| NLR ≥5 = worse		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Elevated NLR = worse
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| HR ~~2.7~~; 1-year survival ~~26% vs. 60%~~		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Elevated HR; significantly reduced 1-year survival
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Meta-analysis~~, n=1,533~~<ref name="nlr-meta" />		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Meta-analysis<ref name="nlr-meta" />
	\|-		\|-
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| '''Platelet Count'''		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| '''Platelet Count'''
Line 364:		Line 369:
	=== How does the neutrophil-to-lymphocyte ratio predict outcomes? ===		=== How does the neutrophil-to-lymphocyte ratio predict outcomes? ===

	The NLR is a simple blood test ratio that serves as a powerful prognostic biomarker. An NLR ~~of 5 or~~ higher ~~carries a~~ hazard ratio ~~of 2.7~~ for death, with 1-year survival ~~dropping from 60% (NLR below 5) to just 26%~~. NLR can be monitored throughout treatment to track disease trajectory and treatment response.<ref name="nlr-meta" />		The NLR is a simple blood test ratio that serves as a powerful prognostic biomarker. An elevated NLR is associated with a significantly higher hazard ratio for death, with substantially reduced one-year survival rates. NLR can be monitored throughout treatment to track disease trajectory and treatment response.<ref name="nlr-meta" />

	=== Does treatment at a specialized center improve prognosis? ===		=== Does treatment at a specialized center improve prognosis? ===
Line 383:		Line 388:
	* '''104 months''' median survival for peritoneal mesothelioma patients achieving complete cytoreduction (CC-0) with HIPEC<ref name="mnet-hipec" />		* '''104 months''' median survival for peritoneal mesothelioma patients achieving complete cytoreduction (CC-0) with HIPEC<ref name="mnet-hipec" />
	* '''0.70 AUC''' achieved by the 2025 PLECH score for predicting 1-year overall survival, the most accurate mesothelioma prognostic model<ref name="plech" />		* '''0.70 AUC''' achieved by the 2025 PLECH score for predicting 1-year overall survival, the most accurate mesothelioma prognostic model<ref name="plech" />
	* '''~~2.7~~ hazard ratio''' for death when neutrophil-to-lymphocyte ratio ~~exceeds 5~~, ~~dropping 1-year~~ survival ~~from 60% to 26%~~<ref name="nlr-meta" />		* '''Elevated hazard ratio''' for death when neutrophil-to-lymphocyte ratio is high, with significantly reduced survival rates<ref name="nlr-meta" />
	* '''10.0% vs. 14.6%''' 90-day mortality at high-volume versus lower-volume mesothelioma surgery centers<ref name="volume-outcomes" />		* '''10.0% vs. 14.6%''' 90-day mortality at high-volume versus lower-volume mesothelioma surgery centers<ref name="volume-outcomes" />

Line 460:		Line 465:
	<ref name="mattorney-sarcomatoid">[https://mesotheliomaattorney.com/mesothelioma/types/sarcomatoid/ Sarcomatoid Mesothelioma Guide], MesotheliomaAttorney.com</ref>		<ref name="mattorney-sarcomatoid">[https://mesotheliomaattorney.com/mesothelioma/types/sarcomatoid/ Sarcomatoid Mesothelioma Guide], MesotheliomaAttorney.com</ref>
	<ref name="mattorney-compensation">[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation Guide], MesotheliomaAttorney.com</ref>		<ref name="mattorney-compensation">[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation Guide], MesotheliomaAttorney.com</ref>
			<ref name="ecog-mpem-2021">[https://pubmed.ncbi.nlm.nih.gov/34650746/ Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma], Wang T, Li H, Ye B, Zhang D. ''American Journal of Translational Research'' 2021;13(9):10712–10720 (PMID 34650746) — multivariate analysis identified ECOG score as an independent prognostic factor (OR 3.91, p=0.017) alongside TNM stage and treatment modality</ref>
			<ref name="checkmate743-bla">[https://pubmed.ncbi.nlm.nih.gov/33485464/ First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial], Baas P, Scherpereel A, et al. ''Lancet'' 2021 (PMID 33485464)</ref>
			<ref name="checkmate743-5yr">[https://pubmed.ncbi.nlm.nih.gov/41734361/ Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743], Scherpereel A, Baas P, et al. ''Journal of Clinical Oncology'' 2026 (PMID 41734361) — 5-year OS 14% vs. 6%</ref>
			<ref name="danish-pm-2025">[https://pubmed.ncbi.nlm.nih.gov/41179988/ Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines], Panou V, Sørensen JB, Ravn J, Santoni-Rugiu E. ''European Clinical Respiratory Journal'' 2025;12(1):2580795 (PMID 41179988)</ref>
	</references>		</references>

MesotheliomaSupport: RON: Add OG/Twitter meta — type=Article, twitter_card=summary_large_image

2026-04-25T14:17:27Z

RON: Add OG/Twitter meta — type=Article, twitter_card=summary_large_image

← Older revision		Revision as of 14:17, 25 April 2026
Line 6:		Line 6:
	\|author=Danziger & De Llano Legal Team		\|author=Danziger & De Llano Legal Team
	\|published_time=2026-03-08		\|published_time=2026-03-08
	}}		\|type=Article
			\|twitter_card=summary_large_image}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-

MesotheliomaSupport: Add At-a-Glance section per template standard

2026-04-23T20:09:11Z

Add At-a-Glance section per template standard

← Older revision		Revision as of 20:09, 23 April 2026
Line 39:		Line 39:

	Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />		Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />

			== At-a-Glance ==

	'''Mesothelioma prognosis at a glance:'''		'''Mesothelioma prognosis at a glance:'''
Line 50:		Line 52:
	* '''Peritoneal patients with complete surgery survive 8.7 years''' — median 104 months after cytoreductive surgery with HIPEC		* '''Peritoneal patients with complete surgery survive 8.7 years''' — median 104 months after cytoreductive surgery with HIPEC
	* '''High-volume centers reduce surgical death by 31%''' — 10.0% versus 14.6% ninety-day mortality at specialized facilities		* '''High-volume centers reduce surgical death by 31%''' — 10.0% versus 14.6% ninety-day mortality at specialized facilities



	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Add at-a-glance listicle between Overview and Key Facts

2026-03-08T20:56:40Z

Add at-a-glance listicle between Overview and Key Facts

← Older revision		Revision as of 20:56, 8 March 2026
Line 39:		Line 39:

	Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />		Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />

			'''Mesothelioma prognosis at a glance:'''
			* '''Treated patients survive 12–21 months on average''' — but individual outcomes vary dramatically based on stage, histology, age, gender, and molecular markers
			* '''BAP1 mutation carriers survive 7 times longer''' — median 5 years compared to less than 1 year for non-carriers, making genetic testing critical
			* '''Epithelioid subtype doubles survival''' — 14–18 months median versus 4–8 months for sarcomatoid, with 5-year rates of 14% versus 4%
			* '''Women survive nearly 3 times longer''' — 13.4% five-year survival versus 4.5% for men, with 22% reduced mortality risk (HR 0.78)
			* '''Age under 50 means 39% five-year survival''' — compared to just 4.5% for patients 75 and older, a nearly 9-fold difference
			* '''PLECH score (2025) predicts survival most accurately''' — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems
			* '''NLR ≥5 signals 2.7 times higher mortality''' — one-year survival drops from 60% to 26% based on this simple blood test ratio
			* '''Peritoneal patients with complete surgery survive 8.7 years''' — median 104 months after cytoreductive surgery with HIPEC
			* '''High-volume centers reduce surgical death by 31%''' — 10.0% versus 14.6% ninety-day mortality at specialized facilities

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Add Quick Statistics listicle section for GEO; restore Key Facts wikitable

2026-03-08T20:35:07Z

Add Quick Statistics listicle section for GEO; restore Key Facts wikitable

@@ Line 42: / Line 42: @@
 == Key Facts ==
 * '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />
 * '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />
@@ Line 52: / Line 57: @@
 * '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />
 * '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />
 == What Factors Determine Mesothelioma Prognosis? ==
@@ Line 351: / Line 357: @@
 Clinical practice guidelines (2023, European Journal of Human Genetics) recommend genetic counseling and testing for patients with mesothelioma, particularly those diagnosed at younger ages, those with family history of mesothelioma or related cancers (uveal melanoma, renal cell carcinoma), and those with limited or no known asbestos exposure history. BAP1 status has implications for prognosis, treatment planning, and family member surveillance.<ref name="bap1-guidelines" /><ref name="bap1-case" />
 == Get Help ==

MesotheliomaSupport: Fix Key Facts: convert table-wrapped bullets to plain listicle

2026-03-08T20:30:08Z

Fix Key Facts: convert table-wrapped bullets to plain listicle

← Older revision		Revision as of 20:30, 8 March 2026
Line 42:		Line 42:
	== Key Facts ==		== Key Facts ==

	~~{\| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"~~
	\|-
	~~! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Prognosis~~
	\|-
	~~\| style="padding:15px;" \|~~
	* '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />		* '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />
	* '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />		* '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />
Line 57:		Line 52:
	* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />		* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />
	* '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />		* '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />
	\|}

	== What Factors Determine Mesothelioma Prognosis? ==		== What Factors Determine Mesothelioma Prognosis? ==

MesotheliomaSupport: Add comprehensive Mesothelioma Prognosis page with prognostic scoring systems, BAP1 mutations, blood biomarkers, and age-specific survival data

2026-03-08T20:17:19Z

Add comprehensive Mesothelioma Prognosis page with prognostic scoring systems, BAP1 mutations, blood biomarkers, and age-specific survival data

Show changes

MesotheliomaSupport: Create redirect

2026-02-20T01:26:05Z

Create redirect

New page

#REDIRECT [[Mesothelioma Survival Statistics]]